Weibo ZHANG

Weibo ZHANG

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2025 in Frontiers in Psychiatry
Verified
Journal Article
Open access
PDF file
KCKe Chen
Ke Chen
LWLina Wang
Lina Wang
HNHoumei Ning
Houmei Ning
HPHuiqing Pan
Huiqing Pan
WZWeibo ZHANG
Weibo ZHANG
Objective: The present study sought to evaluate the correlation between cognitive impairment (CI) and inflammatory indicators such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammatory index (SII) in schizophrenia patients.Methods: This study included 331 schizophrenia inpatients. General data and laboratory findings (neutrophil, lymphocyte, platelet, etc.) were gathered, and then calculating NLR, PLR, and SII. A Chinese version of the Mini Mental State Examination (MMSE) was used for the assessment of cognitive function, and then the patients in the CI group were categorized into mild CI, moderate CI, and severe CI groups. Comparing the differences in NLR, PLR, and SII between the CN group and the CI group, as well as different CI groups, and analyzing the relationship between the NLR, PLR, and SII and the mechanism of CI in schizophrenia.Results: There were 145 (43.8%) patients with cognitive impairment. Compared to the CN group, the CI group had higher NLR, PLR, and SII than the CN group, although their lymphocyte was lower. The NLR and SII were higher in the moderate CI group than in the mild CI group. NLR, PLR, and SII were significantly inversely correlated with the total score of cognitive function and scores across all aspects, whereas lymphocytes were considerably positively correlated. Higher NLR, PLR, and SII were substantially related to an increased risk of CI, but higher lymphocytes were associated with a decreased risk of CI.Conclusion: NLR, PLR, and SII may be serum inflammatory markers of CI in schizophrenia, and lymphocytes may be protective variables for cognitive function in schizophrenia.

2 January 2025 in BMC Health Services Research
Verified
Journal Article
Open access
PDF file
HYHao Yao
Hao Yao
SHSiyuan He
Siyuan He
FYFei Yan
Fei Yan
WWWei Wang
Wei Wang
HLHanyi Lin
Hanyi Lin
WZWeibo ZHANG
Weibo ZHANG
In recent years, the Chinese government has increased its support for the development of community-based psychiatric rehabilitation (CBPR) services and initiated pilot programs for government purchasing of CBPR services from non-governmental organizations (NGOs) in order to address the inadequacy of the government’s own supply capacity of CBPR services. This study investigated how the NGOs in Shanghai perceived the challenges and opportunities for participating in the provision of government-purchased CBPR services. A qualitative descriptive approach was employed in this study. The local NGOs’ program directors who had been responsible for the provision of government-purchased CBPR services in Shanghai were interviewed regarding their perceptions of the challenges and opportunities. Interview transcripts were coded and analyzed using Braun and Clarke’s thematic analysis method. A total of 19 NGOs’ program directors were interviewed. The challenges perceived by them for NGOs to participate in the provision of government-purchased CBPR services included difficulty with engaging individuals with mental illness and their families, lack of resources, lack of knowledge and skills, inadequate collaborations with other stakeholders, and limitations of services. The opportunities could be grouped into external and internal ones. External opportunities included China’s favorable policy environment, Shanghai’s developed economic environment, and increased public awareness of mental health, while internal opportunities included NGOs’ greater flexibility, high team cohesion, stronger focus on the holistic needs of clients, better resource integration capabilities, and ability to provide long-term follow-up and support for clients. Based on the findings, recommendations for future actions are provided in the areas of research, public awareness, funding, training, referrals, collaboration, and service designing to improve the mechanism of government purchasing of CBPR services from NGOs in China.

4 September 2025 in eClinicalMedicine
Verified
Journal Article
Open access
ZLZhao Liu
Zhao Liu
DZDian Zhu
Dian Zhu
ZZZhiwen Zhang
Zhiwen Zhang
YLYanli Liu
Yanli Liu
HYHongyi Yang
Hongyi Yang
JCJun CAI
Jun CAI
Medication non-adherence is a significant challenge in the management of schizophrenia, with non-adherence rates ranging from 30 to 70%. Digital interventions may address barriers to adherence and improve outcomes. We aimed to evaluate the efficacy of a narrative-based psychoeducational intervention in improving medication adherence, attitudes, psychological state, and quality of life in individuals with stable schizophrenia. This multicentre, parallel-group randomised controlled trial with blinded outcome assessment was conducted at seven community rehabilitation centres. Eligible patients (aged 18–60 years) had a diagnosis of schizophrenia (ICD-10) in a clinically stable phase, had normal vision and hearing, and were able to use a smartphone independently. Upon enrolment, participants were randomly allocated (1:1) to either the intervention group or the control group. The intervention group received standard community rehabilitation plus a narrative-based psychoeducational intervention three times per week for 3 months, while the control group received standard community rehabilitation only. Co-primary outcomes were medication adherence and medication attitude, as assessed using validated self-report questionnaires: the Morisky Medication Adherence Scale-8 (MMAS-8) and the Drug Attitude Inventory (DAI-10), respectively, at: baseline (T0, prior to randomization), post-intervention (T1, after 3 months of intervention), 1-month follow-up (T2, 4 months from baseline), and 3-month follow-up (T3, 6 months from baseline). This trial is registered with ClinicalTrials.gov, NCT06175559. Between Feb 1 and March 25, 2024, 72 participants were enrolled. Two participants withdrew (distance concerns). Data collection continued until October 30, 2024. Among the 70 participants who completed assessments (mean [SD] age, 44.20 [8.06] years; 27 women [38.57%], 43 men [61.43%]), significant between-group differences emerged over time. The psychoeducational intervention group reported greater positive changes than the control group in medication adherence (β = 0.75 [95% CI, 0.10–1.40]; P = 0.02) and medication attitude (β = 2.29 [0.42–4.15]; P = 0.02) at the T1, and the difference was sustained at 3-month follow-up for adherence (β = 1.65 [0.68–2.62]; P < 0.001) and attitude (β = 3.42 [1.38–5.45]; P = 0.001). Older patients showed significantly better outcomes in medication attitudes (β = 1.56 [0.03–3.10]; P = 0.05) and clinical symptoms (β = −2.43 [−4.83 to −0.04]; P = 0.05), while those with lower education levels had significantly better medication adherence (β = 0.93 [0.20–1.67]; P = 0.01) and social relationships (β = 0.87 [0.23–1.52]; P = 0.01). Our findings suggest that narrative-based psychoeducational interventions can improve medication adherence in individuals with schizophrenia, with sustained effects. Future studies should investigate the long-term effectiveness and implementation of narrative-based psychoeducation interventions in larger and more diverse patient populations. 10.13039/501100003399 Shanghai Municipal Science and Technology Commission 2024 “Science and Technology Innovation Action Plan” Medical Innovation Research Field Program, the 10.13039/501100003395 Shanghai Municipal Education Commission , Shanghai Jiao Tong University 2024 Medical-Industrial Intersection Research Fund, and Shanghai Jiao Tong University Medical-Industrial Interdisciplinary Youth Program.

2 October 2025 in Clinical Psychology Review
Verified
Journal Article
Closed access
HYHongyi Yang
Hongyi Yang
FCFangyuan Chang
Fangyuan Chang
DZDian Zhu
Dian Zhu
MFMuroi Fumie
Muroi Fumie
ZLZhao Liu
Zhao Liu
JCJun CAI
Jun CAI

9 April 2024 in BMJ Open
Verified
Journal Article
Open access
PDF file
YZYouwei Zhu
Youwei Zhu
SHSiyuan He
Siyuan He
YLYanli Liu
Yanli Liu
CCChunmei Chen
Chunmei Chen
XGXiaolei Ge
Xiaolei Ge
BXBin Xie
Bin Xie
Introduction Drivers for remission, relapse and violence-related behaviour among patients with schizophrenia are the most complicated issue. Methods and analysis This study aims to recruit a longitudinal cohort of patients with schizophrenia. Two suburban districts and two urban districts were randomly selected according to health service facilities, population, geographical region and socioeconomic status. Individuals (>18 years old) who received a diagnosis of schizophrenia following the International Classification of Diseases (10th edition) criteria within the past 3 years will be invited as participants. Assessments will be carried out in local community health centres. Data will be used to (1) establish a community-based schizophrenia cohort and biobank, (2) prospectively determine the course of multidimensional functional outcomes of patients with schizophrenia who are receiving community-based mental health treatment, and (3) map the trajectories of patients with schizophrenia and prospectively determine the course of multidimensional outcomes based on the differential impact of potentially modifiable moderators. Ethics and dissemination The study has been reviewed and approved by the Human Research Ethics Committee of Shanghai Mental Health Center (2021-67). Results of the study will be disseminated through peer-reviewed journals. If effective, related educational materials will be released to the public.

15 June 2026 in Actas Españolas de Psiquiatría
Verified
Journal Article
Open access
PDF file
YZYu Zhou
Yu Zhou
PZPanPan Zhang
PanPan Zhang
FWFeng Wang
Feng Wang
WZWeibo ZHANG
Weibo ZHANG
YJYiHua Jing
YiHua Jing
Background: Schizophrenia is a severe mental disorder associated with significantly higher mortality risk than the general population, constituting a major public health challenge. Clarifying temporal trends in mortality among patients with schizophrenia helps inform targeted clinical and public health interventions. To assess changes in mortality rates over the last 2 years in patients with schizophrenia from one district of Shanghai, China. Methods: This longitudinal cohort study assessed the mortality of individuals with schizophrenia (n = 5234) from April 1, 2021, to March 31, 2023. The early cohort (up to March 31, 2022) contained 5207 individuals and the late cohort (up to March 31, 2023) contained 5114 individuals. Partitions of Pearson’s chi-square statistic were used to conduct pairwise comparisons. A multivariable Cox proportional hazards model was used to assess the effects of different factors on mortality risk. Data were drawn from the official Shanghai database used for following-up individuals with severe mental health disorders. Results: The total number of deaths was 370. Of these, 120 occurred in the early cohort (2.30% of the cohort) and 250 in the late cohort (4.89% of the cohort). Individuals with schizophrenia in the late cohort had a 5.08- fold increased mortality risk than individuals in the general population. In the early cohort, mortality rates remained relatively stable (0.29%–0.48%). There were peaks in mortality rates (2.23%) in December 2022 and January 2023. Men had a higher risk of mortality than women (hazard ratio [HR], 1.294; 95% confidence interval [CI], 1.035–1.618; p = 0.024). Age was a contributing factor to the mortality of people with schizophrenia (HR, 1.048; 95% CI, 1.040– 1.056; p < 0.001). Being unmarried (HR, 1.956; 95% CI, 1.522–2.513; p < 0.001), divorced (HR, 1.481; 95% CI, 1.010–2.170; p = 0.044), or widowed (HR, 1.334; 95% CI, 0.958–1.856; p = 0.088) was associated with a high risk of mortality. Age of onset (HR, 1.046; 95% CI, 1.037– 1.054; p < 0.001) and illness duration (HR, 1.044; 95% CI, 1.037–1.051; p < 0.001) were associated with high mortality risk. The late cohort showed a higher mortality rate than the early cohort (HR, 2.427; 95% CI, 1.467–4.014; p = 0.001). The mortality of patients with schizophrenia was notsignificantly related to education level, economic status, or symptom onset. Conclusions: These findings highlight trends in schizophrenia mortality since April 2021. Compared with the general population, individuals with schizophrenia had higher mortality risk, particularly adults aged ≥65 years and women with low education.